Introduction {#ss1}
============

Sitagliptin belongs to a novel class of oral antihyperglycemic agents (OHA)[^1^](#b1){ref-type="ref"}. It exerts its effects through the inhibition of DPP4 activity, which increases levels of the two plasma incretin hormones, glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP)[^2--5^](#b2 b3 b4 b5){ref-type="ref"}. These two incretin hormones play an important role in maintaining glucose homeostasis by stimulating insulin secretion from pancreatic β‐cells, and sitagliptin can produce a twofold to threefold increase in their elevation[^6--8^](#b6 b7 b8){ref-type="ref"}. GLP‐1 also inhibits glucagon secretion, reducing food intake, and delaying gastric emptying. In addition, because it has been reported that active GLP‐1 levels in both healthy subjects and patients with type 2 diabetes mellitus are remarkably low[^9^](#b9){ref-type="ref"}, and the several mechanisms by which sitagliptin lowers blood glucose are unique among the available OHA, multiple aspects of the clinical profiles of the patients must be analyzed to understand the action of sitagliptin.

Secretory units of islets in transplantation (SUIT) is an index calculated from the fasting plasma glucose (FPG, mg/dL) and fasting C‐peptide (F‐CPR, ng/mL) levels using the formula: 1485 × F‐CPR/(FPG − 61.8)[^10,11^](#b10 b11){ref-type="ref"}. SUIT has been shown to measure β‐cell function in type 2 diabetes mellitus quite well, and is a useful tool in the management of diabetes patients[^10^](#b10){ref-type="ref"}. We carried out a retrospective analysis of clinical data extracted from the records of 40 adult Japanese patients with type 2 diabetes mellitus who received sitagliptin 50 mg/day from December 2009 to November 2010. We found in the present study that SUIT can be a clinical marker that correlates with the efficacy of sitagliptin.

Materials and Methods {#ss2}
=====================

Patients {#ss3}
--------

We carried out a retrospective analysis of 40 Japanese patients (29 male and 11 female) with type 2 diabetes mellitus who were given sitagliptin 50 mg for treatment. The study protocol was approved by local institutional review boards. We selected type 2 diabetes mellitus patients who were at least 18 years‐of‐age, had been on stable treatment for at least 4 months before the start of sitagliptin and had completed \>20 weeks of treatment. We excluded patients with a history of type 1 diabetes, liver disease, major gastrointestinal surgery or renal dysfunction (Cr \> 1.5 mg/dL). Their age was 65.1 ± 12.6 years, body mass index (BMI) 25.2 ± 3.1 kg/m^2^ and the duration of diabetes was 10.6 ± 7.1 years ([Table 1a](#t1){ref-type="table-wrap"}). Among the 40 patients, nine patients were drug‐naïve and the other 31 patients had received one to three other oral antihyperglycemic agents (sulfonylurea 27 patients, metformin 14 patients, thiazolidine 8 patients, α‐glucosidase inhibitor 3 patients). During the study period, other oral antihyperglycemic agents were not changed.

######  (a) Summary of patients' characteristics. (b) Summary of parameters at baseline and week 20

  ------------------------------ --------------
  \(a\)                          
  Sex (*n*)                      
   Male                           29
   Female                         11
  Age (years)                    65.1 ± 12.6
  BMI (kg/m^2^)                  25.2 ± 3.1
  Duration of diabetes (years)   10.6 ± 7.1
  Triglyceride (mg/dL)           105.1 ± 38.8
  ------------------------------ --------------

  \(b\)                                                     
  ------------- -------------- -------------- ------------- -------------
  HbA~1c~ (%)   7.53 ± 0.65    6.80 ± 0.60    0.73 ± 0.58   *P* \< 0.01
  FPG (mg/dL)   155.2 ± 29.4   131.2 ± 22.3   24.0 ± 25.9   *P* \< 0.01
  CPR (ng/mL)   1.76 ± 0.96    1.77 ± 1.05    −0.3 ± 2.2    NS
  SUIT          28.5 ± 14.0    38.6 ± 17.0    10.4 ± 10.1   *P* \< 0.01

Data are mean ± SD values. *P *\< 0.01 vs baseline. BMI, body mass index; CPR, C‐peptide; FPG, fasting plasma glucose; HbA~1c~, glycated hemoglobin; SUIT, secretory units of islets in transplantation.

Statistical Analysis {#ss4}
--------------------

All data analyses were carried out using PASW statistics 18 for Windows (SPSS Inc., Chicago, IL, USA). A *P*‐value of \<0.05 was considered statistically significant. Data were expressed as mean ± SD values. For HbA~1c~, FPG and SUIT values, paired *t*‐test was applied. A multiple regression analysis was carried out to obtain the correlation coefficient (*R*) and regression coefficient (β) of independent variables that predict the dependent variables. SUIT was calculated from fasting plasma glucose (FPG, mg/dL) and C‐peptide (F‐CPR, ng/mL) levels using the formula: 1485 × F‐CPR/(FPG − 61.8). The values of HbA~1c~ are expressed using National Glycohemoglobin Standardization Program values. ΔHbA~1c~, ΔSUIT and ΔCPR represent the difference between the baseline value and the week 20 value of HbA~1c~, SUIT and CPR, respectively.

Results {#ss5}
=======

The glycemic characteristics of baseline and week 20 are listed in [Table 1b](#t1){ref-type="table-wrap"}. Mean HbA~1c~ was 7.53 ± 0.65% and FPG was 155.2 ± 29.4 mg/dL. At week 20, sitagliptin produced significant reductions from baseline in HbA~1c~ to 6.80 ± 0.60% (*P \< *0.01) and in FPG to 131.2 ± 22.3 mg/dL (*P* \< 0.01). The mean change from baseline HbA~1c~ was 0.73 ± 0.58%, and the degree of HbA~1c~ decline ranged from −0.7 to 2.6%. The changes from baseline FPG were 24.0 ± 25.9 mg/dL. The baseline SUIT index was 28.5 ± 14.0. Sitagliptin produced a significant increase in SUIT index up to 38.6 ± 17.0 at week 20 (*P* \< 0.01). The increment of SUIT was 10.4 ± 10.1 on average and in each case showed a distribution ranging from −11.3 to 38.4. To elucidate the factors correlating with the efficacy of sitagliptin, we carried out a univariate analysis between the degree of HbA~1c~ decline (ΔHbA~1c~) and several parameters: sex, age, the duration of diabetes, BMI, triglyceride (baseline), C‐peptide (baseline), degree of C‐peptide increment (ΔCPR), HbA~1c~ (baseline), SUIT (baseline) and degree of SUIT increment (ΔSUIT; [Table 2a](#t2){ref-type="table-wrap"}). A significant correlation was found between ΔHbA~1c~ and HbA~1c~ (baseline; *r* = 0.572, *P* \< 0.01) and between ΔHbA~1c~ and ΔSUIT (*r* = 0.454, *P* \< 0.01) ([Table 2a](#t2){ref-type="table-wrap"}, [Figure 1](#f1){ref-type="fig"}). ΔHbA~1c~ had no significant correlation with age, duration of diabetes, triglyceride, CPR (baseline), ΔCPR, SUIT (baseline) or BMI ([Table 2a](#t2){ref-type="table-wrap"}). Subsequent multivariate analysis showed HbA~1c~ (baseline; β = 0.580, *P* \< 0.001) and ΔSUIT (β = 0.308, *P *\< 0.05) as significant independent determinants of ΔHbA~1c~. These two variables explained 53% of the variance in HbA~1c~ response ([Table 2b](#t2){ref-type="table-wrap"}). We also carried out univariate correlation analyses of different variables with ΔSUIT ([Table 2c](#t2){ref-type="table-wrap"}). ΔSUIT had no significant correlation with sex, age, duration of diabetes, BMI, SUIT (baseline), CPR (baseline), ΔCPR or TG (baseline; [Table 2c](#t2){ref-type="table-wrap"}).

######  (a) Univariate correlation of degree of glycated hemoglobin decline to the parameters. (b) Independent determinants of ΔHbA~1c~. (c) Univariate correlation of degree of secretory units of islets in transplantation increment to the parameters

  \(a\)                                   
  ------------------------------ -------- --------
  Sex                            −0.151   NS
  Age (years)                    −0.061   NS
  Duration of diabetes (years)   0.131    NS
  BMI (kg/m^2^)                  0.117    NS
  HbA~1c~ (baseline)             0.572    \<0.01
  SUIT (baseline)                −0.193   NS
  CPR (baseline)                 0.005    NS
  ΔCPR (0--20 weeks; ng/mL)      0.033    NS
  TG (0 weeks; mg/dL)            −0.208   NS
  ΔSUIT (0--20 weeks)            0.454    \<0.01

  \(b\)                                           
  --------------------- ------- --------- ------- -------
  HbA~1c~ (baseline)    0.580   \<0.001   0.631   0.531
  ΔSUIT (0--20 weeks)   0.308   \<0.05             

  \(c\)                                   
  ------------------------------ -------- ----
  Sex                            0.85     NS
  Age (years)                    0.007    NS
  Duration of diabetes (years)   −0.062   NS
  SUIT (baseline)                −0.085   NS
  CPR (baseline)                 0.184    NS
  ΔCPR (0--20 weeks; ng/mL)      0.133    NS
  TG (0 weeks, mg/dL)            0.064    NS

BMI, body mass index; CPR, C‐peptide; HbA~1c~, glycated hemoglobin; SUIT, secretory units of islets in transplantation; TG, triglyceride.

![ Correlation of degree of secretory units of islets in transplantation increment (ΔSUIT) and degree of glycated hemoglobin decline (ΔHbA~1c~).](jdi-2-377-g1){#f1}

Discussion {#ss6}
==========

In the present study, sitagliptin produced a significant reduction in HbA~1c~ of an average of 0.73 ± 0.58% at week 20, which is comparable to previously reported data in Japanese type 2 diabetes mellitus[^12^](#b12){ref-type="ref"}. The degree of response to sitagliptin in each case showed a distribution from −0.7 to 2.6% at week 20. Sitagliptin became available globally 3 years ago; it and other DPP4 inhibitors lower blood glucose by novel mechanisms. At present, the mechanism underlying the distinct action of sitagliptin is not well understood. In the present study, we found that sitagliptin caused a significant increase in SUIT, an index of β‐cell function, with an average increment of 10.4 ± 10.1 at week 20. Improvement of β‐cell function by sitagliptin treatment in type 2 diabetes mellitus estimated by homeostasis model assessment‐β (HOMA‐β) has been reported by many investigators[^12--19^](#b12 b13 b14 b15 b16 b17 b18 b19){ref-type="ref"}. HOMA‐β by 50 mg sitagliptin was found to be improved in Japanese patients by 15.5%[^10^](#b10){ref-type="ref"}, which is comparable with the increment of SUIT found in the present study. Interestingly, the response of SUIT to sitagliptin showed a distribution from −11.3 to 38.4. Multivariate analysis in the present study showed HbA~1c~ (baseline; β = 0.580, *P *\< 0.001) and ΔSUIT (β = 0.308, *P* \< 0.05) as significant independent determinants of ΔHbA~1c~. These two variables explained 53% of the variance in HbA~1c~ response. It was reported in several studies that sitagliptin decreases HbA~1c~ more in case the HbA~1c~ at the baseline is higher[^20--22^](#b20 b21 b22){ref-type="ref"}. Therefore, it is suggested that the group of patients recruited in the present study was appropriate to evaluate the efficacy of sitagliptin, although the number of the patients was small. The degree of decline of HbA~1c~ had no significant correlation with sex, age, duration of diabetes, BMI, SUIT (baseline), CPR (baseline), the degree of increment of C‐peptide, or triglyceride. These results suggest that the response of SUIT to sitagliptin can be a clinical marker that correlates with the efficacy of sitagliptin. As no significant correlation was found between ΔSUIT and several other variables, the difference in the response of SUIT to sitagliptin remains to be elucidated. However, there is one report in which treatment of type 2 diabetes mellitus patients with sitagliptin improved β‐cell function estimated by C‐peptide minimal model of meal test and a correlation was found between β‐cell function parameters and the reductions in HbA~1c~[^22^](#b22){ref-type="ref"}. Considering that SUIT is an index that correlates well with the C‐peptide levels stimulated by glucagon in type 2 diabetes mellitus[^10^](#b10){ref-type="ref"}, one possible explanation is that the increment of SUIT represents an improvement in the response of insulin secretion. At present, because the number of patients in the present study was small, further clinical analysis recruiting a large number of patients is required to clarify the mechanism of the response of SUIT.

In conclusion, the present results suggest that the SUIT index might be a useful clinical marker of the efficacy of DPP4 inhibitors in the treatment of type 2 diabetes mellitus.
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